Background: This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. Methods: The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest and the cumulative genotype, together with virological outcomes after the latest genotype, were measured in treatmentexperienced patients who underwent ≥2 resistance tests Treatment guidelines indicate that the assessment of HIV-1 drug resistance is a central part of the management of patients experiencing viraemia while on antiretroviral therapy (ART) [1] [2] [3] . Genotypic testing by population sequencing has become established as a rapid and relatively inexpensive methodology for detecting antiretroviral drug resistance and is widely used in routine clinical practice [1, 4, 5] . Understanding its limitations and ensuring the results are interpreted correctly are essential to guide appropriate treatment selection [6] [7] [8] .
Treatment guidelines indicate that the assessment of HIV-1 drug resistance is a central part of the management of patients experiencing viraemia while on antiretroviral therapy (ART) [1] [2] [3] . Genotypic testing by population sequencing has become established as a rapid and relatively inexpensive methodology for detecting antiretroviral drug resistance and is widely used in routine clinical practice [1, 4, 5] . Understanding its limitations and ensuring the results are interpreted correctly are essential to guide appropriate treatment selection [6] [7] [8] .
Ongoing virus replication under drug pressure leads to the selection, emergence and evolution of drugresistant variants within the viral quasispecies and the accumulation of resistance mutations causes increasing drug resistance and cross-resistance [5] . Once the drug applying selection pressure is discontinued, the resistant variants lose their replication advantage and tend to be outgrown by either wild-type virus in the absence of therapy or by other resistant mutants if treatment is changed unsuccessfully [7, [9] [10] [11] [12] . The previously selected variants persist at low frequency within the quasispecies and are also archived within proviral DNA; these variants can re-emerge rapidly when selection pressure is re-introduced [12, 13] . Antiretroviral drug resistance must therefore be regarded as longlasting. Genotypic resistance testing typically detects resistance mutations in plasma RNA using population sequencing and identifies mutations if they are present in at least 20% of circulating viruses [7] . As a result, mutants present at low frequency in the quasispecies escape detection by routine testing, leading to the apparent disappearance of previously detected resistant variants whenever drug pressure is insufficient to
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Predicting antiretroviral drug resistance from the latest or the cumulative genotype Introduction maintain the mutant [7, [10] [11] [12] . The rate of decline of a resistant mutant within the quasispecies reflects, at least in part, its fitness relative to other variants and is usually rapid for mutations with a high fitness cost such as M184V [14, 15] .
Reflecting these considerations, guidelines recommend that treatment changes in patients experiencing virological failure should take into account the patient's treatment history and both current and previous resistance test results [1] . In clinical practice, however, resistance test results might not be available for all relevant time points in a patient's treatment history. To what extent the availability of historical data affects the prediction of drug resistance and treatment selection after failure remains at present unclear. The aim of this study was to compare in ART-experienced patients undergoing genotypic resistance testing, the levels of drug resistance predicted when considering either the latest genotypic resistance test or the combination of all genotypic resistance tests ever obtained in the patient as a cumulative genotype. In patients who started a new regimen after the last genotypic test, we analysed virological responses according to the treatment genotypic sensitivity score (GSS) as calculated by the latest or the cumulative genotype.
Methods

Study population
The study retrospectively analysed the genotypic resistance test results of treatment-experienced patients from two clinical cohorts attending the Hospital Universitario San Cecilio in Granada, Spain and the Royal Free Hospital in London, UK. The two resistance databases were searched for all patients who underwent at least two genotypic resistance tests while receiving ART between 1999 and 2008. Tests performed in drug-naive patients and in those knowingly undergoing a treatment interruption were excluded. Demographic and clinical data were retrieved from the clinic databases.
Resistance testing
Genotypic resistance testing was performed with the TruGene HIV-1 genotyping kit (Siemens, Barcelona, Spain) at Hospital Universitario San Cecilio and the ViroSeq HIV-1 system (Celera Diagnostics, Alameda, CA, USA) at the Royal Free Hospital. Drug resistance mutations in reverse transcriptase (RT) and protease were classed into major and minor mutations according to the International AIDS Society USA (IAS-USA) drug resistance mutation list (March/April 2008) [16] . All historical resistance tests were re-analysed according to the 2008 IAS-USA list. In addition, regardless of the mutations identified by the IAS-USA list, all sequences and genotypes were submitted to the Stanford University HIV Drug Resistance Database (version 5.1.1).
Analyses
The resistance profile of each patient was determined according to the latest and the cumulative genotype. The cumulative genotype was obtained by summing all the resistance mutations detected in all available resistance tests to produce one genotype for subsequent analysis. Using the Stanford genotypic interpretation system (GIS), the levels of resistance to nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) were graded as susceptible (S), intermediate-level resistance (I) or high-level resistance (R). The Stanford GIS categories 'susceptible' and 'potential low-level resistance' were classed together as S, whereas the categories 'low-level resistance' and 'intermediatelevel resistance' were classed together as I. Changes in the levels of resistance were analysed as a change from S to I or R and conversely from I or R to S. The proportion of patients who showed a change between the latest and the cumulative genotype was calculated. The GSS of the ART regimen started after the latest genotype was obtained by assigning a score of 1 to S, 0.5 to I and 0 to R for each drug in the ART regimen, and then summing the scores. Kappa statistics were used to compare the GSS calculated from the latest genotype ('latest GSS') with that calculated from the cumulative genotype ('cumulative GSS') in order to assess levels of agreement between the two methods of categorising resistance. The interpretation of the degree of concordance between the latest and the cumulative genotype according to the kappa values was as follows: >0.8 excellent; >0.6 to ≤0.8 good; >0.4 to ≥0.6 moderate; >0.2 to ≥0.4 fair; and ≤0.2 poor concordance or no relationship. We then assessed the independent predictive abilities for virological outcomes of the latest GSS and the cumulative GSS by creating regression models to explore viral load changes at three pre-defined time points. As we wanted to assess the added benefit of incorporating previously detected but currently undetectable mutations into the GSS, multivariable models included both the latest GSS and the change in GSS between the latest and the cumulative genotype. The cumulative GSS was not included in the multivariable models due to co-linearity between this variable and the latest GSS and the change in GSS. Other variables that were considered for inclusion in these models were age, gender, ethnicity, risk group, number of resistance tests, number of previous ART regimens, the last plasma HIV-1 RNA load ('viral load') measured before the start of the new regimen (baseline) and the time between the viral load measurement and the start of the new regimen. Statistical analyses were performed using STATA (StataCorp 2001; Stata Statistical Software, version 11.0, College Station, TX, USA). All reported P-values are two-sided using a level of significance of 0.05.
Results
Study population
A total of 227 patients and 632 resistance tests were included in the analysis, comprising 122 patients with 2 tests, 59 patients with 3 tests, 30 patients with 4 tests, 11 patients with 5 tests, and 5 patients with more than 5 tests. The median number of tests per patient was 2 (range 2-9) and the median time between the first and the latest test was 22 months (range 2-76). Among the 227 patients, 163 started a new ART regimen after the latest genotype and had a record of both the composition of the new regimen and subsequent virological responses. The characteristics of the study population at the time of the latest genotype are summarised in Table 1 .
Prevalence of resistance mutations
The median (range) number of major NRTI, NNRTI and PI mutations was 1 (0-7), 0 (0-5) and 0 (0-6), respectively, in the latest genotype and 2 (0-7), 1 (0-5) and 0 (0-6) in the cumulative genotype; the median (range) number of minor PI mutations was 4 (0-12) and 4 (0-12), respectively. Information on the antiretroviral drugs used after the last resistance test was missing for 17 patients (4 and 13 in the two groups, respectively). ART, antiretroviral therapy; IDU, injecting drug user; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor (both ritonavir-boosted and unboosted); RFH, Royal Free Hospital; UHSC, Hospital Universitario San Cecilio. and triple-class resistance, respectively. Reflecting the increased prevalence of resistance, according to the cumulative genotype, numbers changed to 0 (0.0%), 46 (20.3%), 76 (33.5%) and 105 (46.3%), respectively. Table 2 lists the resistance mutations that showed increased prevalence in the cumulative genotype relative to the latest genotype. For the NRTIs, the major mutations that showed the largest increase in prevalence were M184V and the thymidine analogue mutations (TAMs). Other major NRTI mutations showed either a smaller increase in prevalence (K65R, L74V, V75I and F116Y) or were detected at a similar prevalence in the latest and the cumulative genotype (A62V, F77L, Y115F and Q151M). For the NNRTIs, the major mutations that showed the largest increase in prevalence were K103N and Y181C, whereas other major NNRTI mutations showed a smaller increase (L100I, V106A/M, V108I, Y188C/L/H, G190A/S and P225H). For the PIs, the major mutation that showed the largest increase in prevalence was L90M, whereas other major PI mutations showed either a smaller increase in prevalence (D30N, L33F, M46I/L, G48V, I50V, I54L/V/M, V82A/T/S, I84V and N88S) or were detected at a similar prevalence in the latest and the cumulative genotype (V32I, I47V/A, I50L and V82L).
Predicted levels of resistance Figure 1 compares the levels of predicted drug resistance when the Stanford GIS was applied to the latest or the cumulative genotype. This is reported as the proportion of patients showing a change in predicted resistance levels from S in the latest genotype to I or R in the cumulative genotype for each drug in the three drug classes, according to current or prior use of each drug class (NRTIs divided into lamivudine/emtricitabine and other NRTIs, NNRTIs and PIs) at the time of the latest genotype. The prevalence of resistance to all NRTIs increased in the cumulative genotype. For the NNRTIs, there was an increased prevalence of resistance to efavirenz and nevirapine and to a lesser extent etravirine. PIs were the least affected drug class, in particular darunavir and tipranavir were infrequently affected by increased resistance levels when comparing the latest with the cumulative genotype. Changes from I or R to S were unusual. The inclusion of M184V in the cumulative genotype in the presence of TAMs reduced the level of resistance (as predicted by the latest genotype) to zidovudine, stavudine and tenofovir in 2/82 (2.4%), 2/88 (2.3%) and 2/74 (2.7%) patients, respectively.
Predicted drug activity
For the 227 patients, the median (IQR) number of available fully (S) or partially (I) active drugs according to the Stanford GIS was 6 (5-6) for the NRTIs, 3 (1-3) for the NNRTIs and 7 (7-7) for the PIs with the latest genotype; with the cumulative genotype, corresponding values were 5 (4-6) for the NRTIs, 1 (1-3) for the NNRTIs and 7 (7-7) for the PIs. There were 163 patients who started a new ART regimen after the latest genotype and had a record of the composition of the new ART regimen and virological responses during subsequent follow-up (Table 3 ). The GSS of the new regimen was calculated using the Stanford GIS from the latest and the cumulative genotype. The agreement between the latest and the cumulative genotype was 79.1% when the GSS was categorised into 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5 (kappa value 0.73; P<0.0001) and 82.2% when the GSS was categorised into 0-0.5, 1-1.5, 2-2.5, 3-3.5 and ≥4 (kappa value 0.75; P<0.0001). Among the 163 patients, the median (IQR) GSS was 3 (2-3) with both the latest and the cumulative genotype. In 34/163 (20.9%) patients, there was a change in GSS when comparing the latest GSS with the cumulative GSS; the median (IQR) decrease in GSS was 1 (0.5-1). Overall 23/163 (14.1%) patients started a regimen with a GSS <2 according to the latest genotype; the proportion was higher (31/163, 19%) when taking into account the cumulative genotype.
Virological outcomes after the latest genotype
Among the 163 patients with virological follow-up after the latest genotype, viral load measurements were available at week <12 in 127 patients, weeks 12-24 in 135 patients and at week >24 in 114 patients. The median (IQR) time between baseline and each of these time points was 8.9 weeks (6.0-11.0), 20.1 weeks (17.4-23.1) and 35.0 weeks (29.8-45.2), respectively. Following the start of the new ART regimen, the median (IQR) viral load change in log 10 copies/ml was -0.6 (-1.4--0.0) at week <12, -0.7 (-1.6--0.0) at weeks 12-24 and -0.9 (-1.7--0.2) at week >24. Separate multivariable regression models were performed to investigate predictors of viral load changes at these time points including all patients in an intention-to-treat analysis. At week <12, both the latest and the cumulative GSS were predictive of virological responses (Table 4 ). In the multivariable analysis (which excluded the cumulative GSS due to co-linearity between variables), the latest GSS and the baseline viral load were independent predictors of the magnitude of virological responses. The change in GSS observed when comparing the latest with the cumulative genotype was marginally predictive of virological response, whereby a larger reduction in GSS when comparing the cumulative with the latest genotype corresponded to a smaller decrease in viral load.
At weeks 12-24, both the latest and the cumulative GSS were marginally predictive of virological response. In unadjusted analyses there was a mean (95% CI) viral load change of -0.19 (-0.39-0.01; P=0.07) per unit increase with the latest GSS and -0.20 (-0.40--0.01; P=0.04) per unit increase with the cumulative GSS. Neither association was apparent after adjustment in separate multivariable analyses. At week >24 there was no detectable association between latest or cumulative GSS and virological response in unadjusted analyses. After adjustment there was a mean (95% CI) viral load change of -0.07 (-0.31-0.17; P=0.57) per unit increase with the latest GSS and -0.05 (-0.28-0.19; P=0.70) per unit increase with the cumulative GSS. At these two time points, factors associated with a greater viral load decline comprised a higher baseline viral load, a lower number of previous regimens and female gender. In addition, risk group was predictive of responses at week >24 with a greater viral load decline observed in homosexual males compared with injecting drug users.
Discussion
This study compared the prevalence of drug resistance mutations and the levels of predicted drug resistance according to the latest or the cumulative genotypic resistance test in treatment-experienced patients with viraemia. Relative to the latest genotype, the cumulative genotype increased the prevalence of resistance mutations and the levels of predicted resistance; the effect was most evident for the NRTIs and NNRTIs and less pronounced for the PIs, particularly darunavir and tipranavir. Among patients who started a new ART regimen after the latest genotype, the GSS of both the latest and the cumulative genotype were predictive of early virological responses. Although only 20.9% of patients showed a reduction in the GSS of the new regimen when using the cumulative rather than the latest genotype, the change was marginally predictive of short-term viral load responses. In this treatment-experienced population, the latest genotype underestimated the levels of NRTI, NNRTI and PI resistance. For the NRTIs, this mainly reflected the underascertainment of M184V, TAMs and to a lesser extent other major mutations, including K65R. Disappearance of M184V from the dominant quasispecies is likely to occur rapidly in the absence of continued selective pressure with lamivudine, emtricitabine and to a lesser extent abacavir [14, 17] , drugs that are typically part of first-line regimens [1] [2] [3] . The higher prevalence of TAMs in the cumulative relative to the latest genotype is likely to reflect prior selection with zidovudine or stavudine [18] , drugs that are now less commonly used in resource-rich countries due to concerns over toxicity [1] [2] [3] . However, other NRTIs can maintain selective pressure on at least some of the TAMs [18] [19] [20] consistent with the overall high prevalence of the mutations, in particular M41L and T215Y/F in the latest genotype. For the NNRTIs, the latest genotype significantly underestimated resistance to efavirenz and nevirapine, reflecting the underascertainment of previously detected K103N and other major NNRTI mutations. These findings are consistent with the use of these NNRTIs in early lines of therapy [1] [2] [3] and with K103N generally being the most prevalent NNRTI resistance mutation in treated populations [21] . A less significant effect was seen for predicted viral sensitivity to etravirine. This might reflect the fact that mutations at codon 181 and other positions involved in etravirine resistance [22, 23] were relatively infrequent. However, in NNRTI-experienced patients, caution should be used in interpreting etravirine resistance results obtained by population sequencing [24] , as responses to the drug are lost rapidly in the absence of a supportive backbone [25] . The latest genotype also underestimated the prevalence of resistance to most PIs. Importantly, however, the prevalence of predicted resistance to darunavir and tipranavir remained low in the cumulative genotype. This is in agreement with observations made in other cohorts, indicating that these drugs are likely to retain significant activity in current populations of treatment-experienced patients, including those with resistance to other PIs [26] . Overall 14% of patients started a regimen with a GSS <2 according to the latest genotype and the proportion was higher (19%) when taking into account the cumulative genotype. Treatment guidelines recommend a GSS of ≥2 and preferably 3 for treatment-experienced patients requiring a new regimen [1] [2] [3] . Selection of a regimen with a GSS <2 can result from a number of factors, including drug availability and tolerability, as well as underestimation of the levels of resistance. In univariable analysis, both the latest and the cumulative GSS were related to the magnitude of early viral load decline after starting a new regimen. We also detected an association between the magnitude of the early virological response and the magnitude of the difference between the cumulative and the latest GSS: a poorer virological response was observed the greater the reduction in GSS when using the cumulative compared with the latest genotype. These observations are consistent with previous studies indicating the value of resistance testing in guiding treatment selection [8] and showing that cumulative analyses improve the estimation of the levels of ART resistance [27] and help to predict responses to salvage therapy [28] . Taken together, the findings indicate that a formal evaluation of the cumulative genotype can guide improvements in drug selection.
Interestingly, the predictive effect of both the latest and the cumulative GSS for virological responses declined over time of follow-up. Short-term predictive effects of GSS have been previously reported [29, 30] . The diminishing predictive effect might have multiple explanations. From a resistance perspective, low frequency and archived mutations might require a period of reselection before their effect becomes apparent [11] [12] [13] 25] . Even a cumulative genotype could fail to identify all resistance mutations in a patient, either because of lack of testing at times of previous treatment failure or due to the relative insensitivity of genotypic testing [7, [10] [11] [12] [13] 24] . Suboptimal virological responses might also be expected in a population with multiple previous lines of therapy (median 5) and limited access to new treatment options such as integrase inhibitors and CCR5 coreceptor antagonists [31, 32] .
There are limitations to this study. Primarily, as in all cohort studies, a role for unmeasured confounders in explaining observed associations cannot be excluded. The number of genotypes from each patient was relatively small. This is indicative of what is available in current clinical cohorts and reflective of the fact that resistance testing might be either not available or not performed in all instances of virological failure prior to a treatment change. Furthermore, the analysis of virological outcomes after the latest genotype was only possible in a subset of patients thus limiting the power of the analysis, although these patients did not show significant differences relative to patients without follow-up data. In addition, the time points of viral load measurement during follow-up varied between patients, reflecting variation in clinical practice. We adjusted for these variables in the multivariable analysis. Importantly, the findings apply to a population with an ART history typical of a mature HIV-1 epidemic in Western Europe and illustrate a principle, the specific details of which are likely to evolve over time as treatment strategies change. Our data show that the cumulative genotype offers a more comprehensive evaluation of the burden of resistance and can guide improvements in the selection of ART regimens for treatment-experienced patients. For current populations of treatment-experienced patients, in the absence of resistance test results from early time points, it should be anticipated that M184V, TAMs and K65R for the NRTIs, major NNRTI mutations and some major PI mutations are likely to be underrepresented in the latest genotype. The effect on PI resistance appears limited especially when considering darunavir and tipranavir, to which the population analysed showed overall infrequent prior exposure. Importantly, our data demonstrated that the GSS of the new ART regimen showed only small differences when comparing the latest with the cumulative genotype. Given that the level of resistance was higher in the cumulative than in the latest genotype, this finding implies that treatment decisions in clinical practice take all available resistance tests as well as ART history into account when selecting a new regimen. The evaluation of a formal cumulative genotype can provide appreciable improvements to drug selection.
